New cholesterol drug tested in liver patients

NCT ID NCT06575959

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This completed Phase 1 study looked at how the experimental cholesterol-lowering drug enlicitide is processed in the body of people with mild or moderate liver impairment compared to healthy volunteers. Twenty participants received a single oral dose, and researchers measured drug levels in the blood over time. The goal is to understand if liver problems affect how the drug is handled, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
enlicitide (oral tablet)
What this could lead to
If successful, this study could help doctors determine the right dose of enlicitide for people with liver problems, making the drug safer and more effective.
What could go wrong
This is a very early, small study (20 people) focused on drug levels, not on whether enlicitide actually lowers cholesterol or improves health. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver disorder liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Orlando Clinical Research Center ( Site 0002)

    Orlando, Florida, 32809, United States

  • The Texas Liver Institute ( Site 0001)

    San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.